Alpheus Medical Raises $52M Series B to Advance Non-Thermal Brain Cancer Therapy
Alpheus Medical is a clinical-stage oncology company advancing an innovative platform that leverages ultrasound to activate cancer-targeting compounds.
Company Name: Alpheus Medical
Location: Chanhassen, MN
Industry: Health Tech
Funding Details:
- Amount: $52M
- Round: Series B
- Investors:
- Lead: HealthQuest Capital, Samsara BioCapital
- Participants: OrbiMed, Action Potential Venture Capital, BrightEdge, Brain Tumor Investment Fund, Sontag Innovation Fund
Purpose of Investment:
To support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of sonodynamic therapy (SDT) in patients with newly diagnosed glioblastoma (GBM).
Leadership:
- President & CEO: Vijay Agarwal, MD, FAANS, FCNS
Product:
Alpheus Medical is developing a novel, non-thermal, tumor-selective treatment for glioblastoma using:
- Low-intensity diffuse ultrasound (LIDU)
- Oral 5-aminolevulinic acid (5-ALA)
This therapy:
- Selectively targets and destroys cancer cells across the brain hemisphere
- Requires no imaging or sedation
- Is delivered in an outpatient setting
About Company:
Alpheus Medical is a clinical-stage oncology company advancing an innovative platform that leverages ultrasound to activate cancer-targeting compounds. Its approach aims to offer a less invasive, outpatient alternative to conventional brain cancer therapies, addressing an urgent unmet need in glioblastoma treatment.
